UAE - Mubasher: ADQ, an Abu Dhabi-based holding company, is considering a potential acquisition of Bausch Health Companies' Egyptian drug unit, known as Amoun Pharmaceutical Co, sources told Bloomberg.
Sources noted that ADQ is studying the acquisition of Amoun, which could be evaluated at $700 million in a sale, as it seeks to expand its healthcare investment portfolio.
Previously known as Valeant Pharmaceuticals International Inc, the global pharmaceutical company Bausch has been reshaping its businesses since becoming infamous on Wall Street for increasing drug prices.
Sources confirmed that no final agreements have been reached, as Amoun could attract other investors.
It is noteworthy to mention that in June, Reuters referred that ADQ is in talks with banks to raise loans and fund its ongoing acquisitions.
